Literature DB >> 2908303

Vasodilating mechanism and response to physiological pressor stimuli of acute doses of carvedilol compared with labetalol, propranolol and hydralazine.

B Tomlinson1, F Bompart, B R Graham, J B Liu, B N Prichard.   

Abstract

There is conflicting evidence regarding the main mechanism of the vasodilating effect with carvedilol at therapeutic doses, and to examine this, single doses of carvedilol 50mg and 100mg were compared with labetalol 400mg, propranolol 160mg, propranolol 80mg plus hydralazine 50mg and placebo in healthy subjects. Dose-response studies (required to increase heart rate or systolic blood pressure by 25 beats/min and 20mm Hg, respectively) were performed with phenylephrine, angiotensin and isoprenaline after each drug, and placebo administration and the effects of physiological pressor stimuli were compared. Phenylephrine systolic pressure dose-response curves were shifted by labetalol (dose ratio 2.4) and both carvedilol doses (dose ratios 50mg 1.9, 100mg 20.2). The slight shift to the right of the angiotensin dose-response curves with hydralazine plus propranolol (dose ratio 1.4) and carvedilol 50mg (dose ratio 1.4) was not significant. beta-Blockade was greatest with propranolol 160mg, followed by carvedilol 100mg, propranolol 80mg plus hydralazine 50mg, carvedilol 50mg and was least with labetalol 400mg (isoprenaline dose ratios required to increase heart rate by 25 beats/min were 55.2, 27.2, 20.2, 14.2, 11.5, respectively). Blood pressure rise with cold pressor and isometric exercise was inhibited most by labetalol. At these acute doses carvedilol displayed some alpha-blockade, but the lower ratio of alpha-blockade to beta-blockade differed from that seen with labetalol, which may account for the different haemodynamic responses at rest and during physiological pressor stimuli with the 2 drugs. There was no definite evidence of direct vasodilator effect.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2908303     DOI: 10.2165/00003495-198800366-00008

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  6 in total

Review 1.  Clinical pharmacology of labetalol.

Authors:  D A Richards; B N Prichard
Journal:  Br J Clin Pharmacol       Date:  1979       Impact factor: 4.335

2.  Efficacy of carvedilol (BM 14,190), a new beta-blocking drug with vasodilating properties, in exercise-induced ischemia.

Authors:  J C Kaski; L Rodriguez-Plaza; J Brown; A Maseri
Journal:  Am J Cardiol       Date:  1985-07-01       Impact factor: 2.778

3.  Haemodynamic effects of carvedilol, a new beta-adrenoceptor blocker and precapillary vasodilator in essential hypertension.

Authors:  R Eggertsen; R Sivertsson; L Andrén; L Hansson
Journal:  J Hypertens       Date:  1984-10       Impact factor: 4.844

4.  Studies on the mode of vasodilating action of carvedilol.

Authors:  G Sponer; K Strein; B Müller-Beckmann; W Bartsch
Journal:  J Cardiovasc Pharmacol       Date:  1987       Impact factor: 3.105

5.  Mechanism of the vasodilatory effect of carvedilol in normal volunteers: a comparison with labetalol.

Authors:  L X Cubeddu; N Fuenmayor; F Varin; V G Villagra; R E Colindres; J R Powell
Journal:  J Cardiovasc Pharmacol       Date:  1987       Impact factor: 3.105

6.  Evaluation of the risk for drug-induced postural hypotension in an experimental model: investigations with carvedilol, prazosin, labetalol, and guanethidine.

Authors:  W Bartsch; G Sponer; K Strein; E Böhm; R G Hooper
Journal:  J Cardiovasc Pharmacol       Date:  1987       Impact factor: 3.105

  6 in total
  14 in total

Review 1.  Newer beta blockers and the treatment of hypertension.

Authors:  D McAreavey; R Vermeulen; J I Robertson
Journal:  Cardiovasc Drugs Ther       Date:  1991-06       Impact factor: 3.727

2.  Effects of carvedilol on renal function.

Authors:  A G Dupont
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

Review 3.  Progress in antihypertensive therapy with a multiple-action drug.

Authors:  B N Prichard; B Tomlinson
Journal:  Drugs       Date:  1988       Impact factor: 9.546

4.  Parallel effects of β-adrenoceptor blockade on cardiac function and fatty acid oxidation in the diabetic heart: Confronting the maze.

Authors:  Vijay Sharma; John H McNeill
Journal:  World J Cardiol       Date:  2011-09-26

Review 5.  Carvedilol. A reappraisal of its pharmacological properties and therapeutic use in cardiovascular disorders.

Authors:  C J Dunn; A P Lea; A J Wagstaff
Journal:  Drugs       Date:  1997-07       Impact factor: 9.546

6.  Effects of MDMA alone and after pretreatment with reboxetine, duloxetine, clonidine, carvedilol, and doxazosin on pupillary light reflex.

Authors:  Cédric M Hysek; Matthias E Liechti
Journal:  Psychopharmacology (Berl)       Date:  2012-06-15       Impact factor: 4.530

Review 7.  Drugs for cardiovascular risk reduction in the diabetic patient.

Authors:  D S Bell
Journal:  Curr Diab Rep       Date:  2001-10       Impact factor: 4.810

Review 8.  Carvedilol. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy.

Authors:  D McTavish; D Campoli-Richards; E M Sorkin
Journal:  Drugs       Date:  1993-02       Impact factor: 9.546

9.  Acute hemodynamic effects of carvedilol in comparison with propranolol in patients with coronary heart disease.

Authors:  T Wendt
Journal:  Clin Investig       Date:  1992

10.  Clinical pharmacology of carvedilol.

Authors:  B Tomlinson; B N Prichard; B R Graham; R J Walden
Journal:  Clin Investig       Date:  1992
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.